Home » Blogs

Graves’ Disease Clinical Trial Recruiting

Graves’ disease is one of the most common overt autoimmune disorders. Patients with Graves’ disease have autoantibodies known as TRAbs which have the ability to stimulate the TSH receptor on thyroid cells causing thyroid overactivity (hyperthyroidism).

Symptoms of hyperthyroidism include goitre, fatigue, heat intolerance, sweating, weight loss despite good appetite, shakiness, inappropriate anxiety, palpitations of the heart, shortness of breath, tetchiness and agitation, poor sleep, thirst, nausea and increased frequency of defaecation. The TRAbs present in patients with Graves’ disease can also cause eye problems in some patients.

Current therapy for Graves’ disease includes treatment with anti-thyroid drugs, destruction of the thyroid using radioiodine, or removing the thyroid through surgery (thyroidectomy). Some treatments like beta-blockers and calcium antagonists may be used to control some of the symptoms of hyperthyroidism.

Illingworth Research Group Ltd are coordinating a study to investigate a potential new drug K1‑70. K1-70 is a monoclonal antibody which is an inhibitor of TSH receptor stimulation by stimulating TRAbs, resulting in a decrease in the over-production of thyroid hormones.  K1‑70 is being developed for the treatment of people who have Graves’ disease, thyroid cancer, and patients who would benefit from controlling thyroid stimulating hormone (TSH) receptor activity. Full study details can be found here.

We require patients with Graves’ disease for this study. For more information, please contact:

  • Volunteer Services team at the Medicines Evaluation Unit on 0800 655 6553 and quote study MEU 15/304 or click here for more details. 
  • Recruitment Team at the Royal Liverpool and Broadgreen Clinical Research Facility between 8.00am and 4.00pm on 0151 706 4863 and quote study CRU/5464 or text CRU/5464 to 07342065915.